Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

Bfgf Peptide Combined with the Pvax-8Cpg Plasmid As Adjuvant is a Novel Anticancer Vaccine Inducing Effective Immune Responses Against Lewis Lung Carcinoma.

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

Novel Vaccine Adjuvant LPS-Hydrogel for Truncated Basic Fibroblast Growth Factor to Induce Antitumor Immunity.

[Antitumor Effect of Recombinant T7 Phage Vaccine Expressing Xenogenic Vascular Endothelial Growth Factor on Lewis Lung Cancer in Mice].

A Novel Liposomal Vaccine Improves Humoral Immunity and Prevents Tumor Pulmonary Metastasis in Mice.

A Novel Combined Conjugate Vaccine: Enhanced Immunogenicity of Bfgf with CRM197 As a Carrier Protein

[The Anti-Tumor Activity of GM-CSF-modified Lung Cancer Cell Vaccine and Its Synergism in Combination with Chemotherapy].

A Nanovaccine Based on Adjuvant Peptide FK‐13 and l‐Phenylalanine Poly(ester amide) Enhances CD8+ T Cell‐Mediated Antitumor Immunity

Vaccination With Allogeneic Gm-Csf Gene-Modified Lung Cancer Cells: Antitumor Activity Comparing With That Induced By Autologous Vaccine

Immune Response of the Vegf/Bfgf Complex Peptide Vaccine and Function of Immune Antibodies in Inhibiting Migration of Huvec Cells and Proliferation of Cancer Cells

Comparison of the Protective Effects of Truncated Bfgf and Native Bfgf Against Murine Lung Carcinoma.

Engineering PEG10 assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination

Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination

Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway.

Inhibition of Tumor Growth with a Vaccine Based on Xenogeneic Homologous Fibroblast Growth Factor Receptor-1 in Mice*

Immunotherapy of Tumor with Vaccine Based on Basic Fibroblast Growth Factor-Activated Fibroblasts

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ